Heart Failure

Merck and Johnson & Johnson (J&J) partner to produce J&J's COVID-19 vaccine; Anthony Fauci, MD, warns against shifting to a single-dose strategy for approved 2-shot vaccines; Medtronic recalls its HVAD Pump Implant Kits.

A comparison of patients with heart failure with preserved ejection fraction (HFpEF) randomized to 1 of 2 physical activities did not show a significant increase in peak oxygen consumption (VO2) vs guideline-based physical activity.

Compared with women with normotensive pregnancies, women who develop various hypertensive disorders during pregnancy have a greater risk of cardiac structure abnormalities in the decade after pregnancy.

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction.

An analysis of 30-year data on participants from the Augusta Heart study shows that Black individuals begin to exhibit potential signs of congestive heart failure earlier than their White counterparts.

A comparison of 2 time periods shows that following an initial decline, hospital admissions for primary management of heart failure rose between 2014 and 2017.

The program is closed with a discussion on how the coronavirus pandemic has affected the standard protocol for treating patients with heart failure.

Machine learning of data from 3 well-known heart studies shows a decline in heart failure risk from drinking at least 1 cup of caffeinated coffee each day.

Compared with a standard-protein diet, a high-protein diet reduced several markers of cardiometabolic risk in patients with heart failure and diabetes who were considered overweight or obese.

An early heart failure follow-up intervention succeeded in increasing referral to and completion of cardiology appointments within 7 days of discharge. The intervention was associated with lower risk of 30-day all-cause emergency department visits, all-cause hospitalizations, or death.

Expert physicians consider how novel agents will affect the treatment paradigm for heart failure.

An investigation of economic data from 3123 US counties, from 2007 to 2016, indicates that the cardiovascular mortality drop the authors saw may be a result of improved economic conditions.

A discussion on the optimal sites of care for patients with heart failure and how differing locations may alter treatment access.

Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.

Women receiving treatment for early-stage breast cancer may have a lower risk of developing heart failure if their therapy regimens include statins.

A meta-analysis found evidence that different kinds of physical activity can help reduce risk of heart failure for the general population.

Both women and men have a greater chance of 90-day hospital readmission when they are considered to be in frail condition from heart failure.

A key opinion leader considers the optimal timing of adding an SGLT2 inhibitor to the treatment for patients with heart failure.

A discussion on the differences of sacubitril-valsartan and spironolactone for the treatment of heart failure.

A discussion on the promising findings from the TOPCAT study.

An expert in the management of heart failure considers the importance of recent findings from the PARALLAX study.

New study findings may pave the way for research into the prognostic value of white matter lesions in heart failure and the impact that HF therapies have on them.

Amid speculation that total blood counts may be associated with heart failure prognosis, researchers find that higher levels of platelet distribution width could be used to predict a worse prognosis for heart failure.

Patients with heart failure should be prioritized during vaccine rollout because of increased mortality risks reportedly associated with coronavirus disease 2019 (COVID-19).

An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile.